In this study, a mouse DCM model was used to demonstrate that dapagliflozin prevents ventricular dilatation and improves cardiac function through its anti-inflammatory effects.​Moreover, dapagliflozin treatment also decreased the levels of NLRP3, IL-6, and IL-1β in both DCM myocardium and H9C2 cardiac cells. This evidence concerns the gene IL1B and Ventriculomegaly.